{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:47:39Z","timestamp":1785527259335,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSD Animal Health Innovation GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Four studies investigated the efficacy of fluralaner\/moxidectin\/pyrantel chewable tablets (Bravecto\u00ae TriUNO) in preventing and treating canine angiostrongylosis; one study also included a formulation of fluralaner\/milbemycin oxime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Studies included eight or 10 dogs\/group. In Studies 1 and 2 (prevention), dogs inoculated with third-stage larvae of\n                      <jats:italic>Angiostrongylus vasorum<\/jats:italic>\n                      on day\u2009\u2212\u200931 or\u2009\u2212\u200928 were randomized to groups by sex and body weight; in Studies 3 and 4 (treatment) by faecal first-stage larvae counts at approximately 8\u00a0weeks post-inoculation (PI). All studies included an untreated control group (CG). Study 1 included three groups treated with formulations of moxidectin\/fluralaner\/pyrantel; minimum moxidectin doses 0.0125, 0.025 or 0.055\u00a0mg\/kg. The formulation with moxidectin at 0.025\u00a0mg\/kg, 99.0% effective in preventing establishment of infection, was adopted as the investigational veterinary product (IVP) for the following studies. Study 2 included a group treated with either the IVP or a combination of fluralaner (10\u00a0mg\/kg) with milbemycin oxime (0.75\u00a0mg\/kg) (IVP-2). In all studies, the IVP was administered once on day 0; in Study 2, IVP-2 was administered on days 0, 31, 62 and 93. In Study 1, efficacy was determined by reductions in geometric mean necropsy worm counts approximately 33\u00a0days post-treatment versus mean CG counts, in the other studies by reductions in mean faecal L1 counts. Study 2 assessed pulmonary changes via thoracic computed tomography. Respiratory signs and serological antibody responses were monitored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In Study 1, all moxidectin doses exceeded 90% efficacy. In Study 2, IVP efficacy (one treatment) at 62\u00a0days was 100.0%; IVP-2 (four treatments) efficacy was 99.8% at 124\u00a0days. Respiratory signs were absent or lower in IVP-treated than CG dogs. In Studies 3 and 4, IVP efficacy was 100% by 3 and 4\u00a0weeks post-treatment, respectively. In all studies, lungworm count reductions in the IVP groups were statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) versus the CG. Serology confirmed\n                      <jats:italic>A. vasorum<\/jats:italic>\n                      infections in all control and IVP-2-treated dogs, and absence of infections in IVP-treated dogs. Treatments were well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A single treatment with Bravecto TriUNO is highly effective in preventing angiostrongylosis and eliminating established\n                      <jats:italic>A. vasorum<\/jats:italic>\n                      infections. Infection-related lung pathology was reduced in treated dogs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-026-07529-4","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:05:27Z","timestamp":1784887527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of a single oral administration of a formulation of fluralaner, moxidectin and pyrantel (BRAVECTO\u00ae TriUNO) in dogs for the treatment and prevention of angiostrongylosis"],"prefix":"10.1186","volume":"19","author":[{"given":"Nadja","family":"Rohdich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Chiummo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Zschiesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Kristin","family":"Raulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"McLoughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Schnyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Schulte","family":"Bocholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Merhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Miki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Strube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Heinau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"7529_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-014-0092-9","volume":"45","author":"HM Elsheikha","year":"2014","unstructured":"Elsheikha HM, Holmes SA, Wright I, Morgan ER, Lacher DW. Recent advances in the epidemiology, clinical and diagnostic features, and control of canine cardio-pulmonary angiostrongylosis. Vet Res. 2014;45:92.","journal-title":"Vet Res"},{"key":"7529_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00436-010-2021-9","volume":"107","author":"M Schnyder","year":"2010","unstructured":"Schnyder M, Fahrion A, Riond B, Ossent P, Webster P, Kranjc A, et al. Clinical, laboratory and pathological findings in dogs experimentally infected with Angiostrongylus vasorum. Parasitol Res. 2010;107:1471\u201380.","journal-title":"Parasitol Res"},{"key":"7529_CR3","doi-asserted-by":"publisher","first-page":"1146713","DOI":"10.3389\/fvets.2023.1146713","volume":"10","author":"MA Taulescu","year":"2023","unstructured":"Taulescu MA, Negoescu A, Ungur A, Toma C, Ionic\u0103 AM, Gal C, et al. Is the Angiostrongylus vasorum infection in domestic dogs underestimated or misdiagnosed? A comprehensive presentation of four lethal cases. Front Vet Sci. 2023;10:1146713.","journal-title":"Front Vet Sci"},{"key":"7529_CR4","unstructured":"European Scientific Counsel Companion Animal Parasites. ESCCAP guideline 01: worm control in dogs and cats, 6th edition; 2021. https:\/\/www.esccap.org\/guidelines\/. Accessed 16 Feb 2025."},{"key":"7529_CR5","first-page":"181","volume":"5","author":"AD Di Cesare","year":"2014","unstructured":"Di Cesare AD, Traversa D. Canine angiostrongylosis: recent advances in diagnosis, prevention, and treatment. Vet Med (Auckl). 2014;5:181.","journal-title":"Vet Med (Auckl)"},{"key":"7529_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10101268","volume":"10","author":"HP Fuehrer","year":"2021","unstructured":"Fuehrer HP, Morelli S, Unterk\u00f6fler MS, Bajer A, Bakran-Lebl K, Dwu\u017cnik-Szarek D, et al. Dirofilaria spp. and Angiostrongylus vasorum: current risk of spreading in Central and Northern Europe. Pathogens. 2021;10:1268.","journal-title":"Pathogens"},{"key":"7529_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/ani15020172","volume":"15","author":"D Traversa","year":"2025","unstructured":"Traversa D, Morelli S, Di Cesare A, Astuti C, Barlaam A, Colombo M, et al. Current enzooticity of Dirofilaria immitis and Angiostrongylus vasorum in Central and Southern Italy. Animals (Basel). 2025;15:172.","journal-title":"Animals (Basel)"},{"key":"7529_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/vr.155.1.16","volume":"155","author":"G Conboy","year":"2004","unstructured":"Conboy G. Natural infections of Crenosoma vulpis and Angiostrongylus vasorum in dogs in Atlantic Canada and their treatment with milbemycin oxime. Vet Rec. 2004;155:16\u20138.","journal-title":"Vet Rec"},{"key":"7529_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/vr.105097","volume":"183","author":"JM Priest","year":"2018","unstructured":"Priest JM, Stewart DT, Boudreau M, Power J, Shutler D. First report of Angiostrongylus vasorum in coyotes in mainland North America. Vet Rec. 2018;183:747.","journal-title":"Vet Rec"},{"key":"7529_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13071-018-2765-0","volume":"11","author":"F Penagos-Tabares","year":"2018","unstructured":"Penagos-Tabares F, Lange MK, Chaparro-Guti\u00e9rrez JJ, Taubert A, Hermosilla C. Angiostrongylus vasorum and Aelurostrongylus abstrusus: neglected and underestimated parasites in South America. Parasit Vectors. 2018;11:208.","journal-title":"Parasit Vectors"},{"key":"7529_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1177\/10406387211011990","volume":"33","author":"JD Kotwa","year":"2021","unstructured":"Kotwa JD, Schnyder M, Jardine CM, Deplazes P, Pearl DL, Berke O, et al. Investigation of the occurrence of Angiostrongylus vasorum in coyotes in southern Ontario. Canada J Vet Diagn Invest. 2021;33:664\u20139.","journal-title":"Canada J Vet Diagn Invest"},{"key":"7529_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2460\/javma.24.06.0408","volume":"262","author":"LBA Williams","year":"2024","unstructured":"Williams LBA, Buswell ML, Perisho NA. First autochthonous case of Angiostrongylus vasorum in a domestic dog in the United States. J Am Vet Med Assoc. 2024;262:1\u20133.","journal-title":"J Am Vet Med Assoc"},{"key":"7529_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/BF00931834","volume":"79","author":"G Bolt","year":"1993","unstructured":"Bolt G, Monrad J, Frandsen F, Henriksen P, Dietz HH. The common frog (Rana temporaria) as a potential paratenic and intermediate host for Angiostrongylus vasorum. Parasitol Res. 1993;79:428\u201330.","journal-title":"Parasitol Res"},{"key":"7529_CR14","unstructured":"Nelson CT, McCall JW, Moorhead A, Starkey L, Ames M. American Heartworm Society: Canine guidelines for the prevention, diagnosis, and management of heartworm (Dirofilaria immitis) infection in dogs 2024. https:\/\/www.heartwormsociety.org\/veterinary-resources\/american-heartworm-society-guidelines. Accessed 16 Feb 2025."},{"key":"7529_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13071-020-3948-z","volume":"13","author":"C Becskei","year":"2020","unstructured":"Becskei C, Thys M, Doherty P, Mahabir SP. Efficacy of orally administered combination of moxidectin, sarolaner and pyrantel (Simparica Trio\u2122) for the prevention of experimental Angiostrongylus vasorum infection in dogs. Parasit Vectors. 2020;13:64.","journal-title":"Parasit Vectors"},{"key":"7529_CR16","doi-asserted-by":"publisher","first-page":"000215","DOI":"10.1136\/vetreco-2016-000215","volume":"5","author":"LE Bird","year":"2018","unstructured":"Bird LE, Bilbrough G, Fitzgerald R, Walker DJ. Determining resolution of Angiostrongylus vasorum in dogs following anthelmintic treatment with an imidacloprid 10 per cent\/moxidectin 2.5 per cent spot-on. Vet Rec Open. 2018;5:000215.","journal-title":"Vet Rec Open."},{"key":"7529_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.vetpar.2007.05.001","volume":"147","author":"JL Willesen","year":"2007","unstructured":"Willesen JL, Kristensen AT, Jensen AL, Heine J, Koch J. Efficacy and safety of imidacloprid\/moxidectin spot-on solution and fenbendazole in the treatment of dogs naturally infected with Angiostrongylus vasorum (Baillet 1866. Vet Parasitol. 2007;147:258\u201364.","journal-title":"Vet Parasitol"},{"key":"7529_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s13071-016-1773-1","volume":"9","author":"W Lebon","year":"2016","unstructured":"Lebon W, Tielemans E, Rehbein S, Dumont P, Yoon S, Beugnet F, et al. Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs. Parasit Vectors. 2016;9:485.","journal-title":"Parasit Vectors"},{"key":"7529_CR19","unstructured":"Milbemax 12.5 mg\/125 mg tablets for dogs, summary of product characteristics, revised February 2025."},{"key":"7529_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetpar.2022.109815","volume":"312","author":"F Beugnet","year":"2022","unstructured":"Beugnet F, Taweethavonsawat P, Traversa D, Fourie J, McCall J, Tielemans E, et al. World Association for the Advancement of Veterinary Parasitology (WAAVP): Second edition of guidelines for evaluating the efficacy of anthelmintics for dogs and cats. Vet Parasitol. 2022;312:109815.","journal-title":"Vet Parasitol"},{"key":"7529_CR21","first-page":"131","volume":"57","author":"G Baermann","year":"1917","unstructured":"Baermann G. Eine einfache Methode zur Auffindung von Ankylostomum (Nematoden) Larven in Erdproben. Geneesk Tidjschr Nederl-Indie. 1917;57:131\u20137.","journal-title":"Geneesk Tidjschr Nederl-Indie"},{"key":"7529_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.vetpar.2011.01.054","volume":"179","author":"M Schnyder","year":"2011","unstructured":"Schnyder M, Tanner I, Webster P, Barutzki D, Deplazes P. An ELISA for sensitive and specific detection of circulating antigen of Angiostrongylus vasorum in serum samples of naturally and experimentally infected dogs. Vet Parasitol. 2011;179:152\u20138.","journal-title":"Vet Parasitol"},{"key":"7529_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.vetpar.2011.09.040","volume":"185","author":"A Schucan","year":"2012","unstructured":"Schucan A, Schnyder M, Tanner I, Barutzki D, Traversa D, Deplazes P. Detection of specific antibodies in dogs infected with Angiostrongylus vasorum. Vet Parasitol. 2012;185:216\u201324.","journal-title":"Vet Parasitol"},{"key":"7529_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.4269\/ajtmh.1990.43.657","volume":"43","author":"BO Duke","year":"1990","unstructured":"Duke BO, Zea-Flores G, Castro J, Cupp EW, Munoz B. Effects of multiple monthly doses of ivermectin on adult Onchocerca volvulus. Am J Trop Med Hyg. 1990;43:657\u201364.","journal-title":"Am J Trop Med Hyg"},{"key":"7529_CR25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2460\/ajvr.1996.57.08.1189","volume":"57","author":"JW McCall","year":"1996","unstructured":"McCall JW, McTier TL, Ryan WG, Gross SJ, Soll MD. Evaluation of ivermectin and milbemycin oxime efficacy against Dirofilaria immitis infections of three and four months\u2019 duration in dogs. Am J Vet Res. 1996;57:1189\u201392.","journal-title":"Am J Vet Res"},{"key":"7529_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0034-5288(91)90117-7","volume":"50","author":"EW Scott","year":"1991","unstructured":"Scott EW, Baxter P, Armour J. Fecundity of anthelmintic resistant adult Haemonchus contortus after exposure to ivermectin or benzimidazoles in vivo. Res Vet Sci. 1991;50:247\u20139.","journal-title":"Res Vet Sci"},{"key":"7529_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijpddr.2020.04.003","volume":"13","author":"PD Jimenez Castro","year":"2020","unstructured":"Jimenez Castro PD, Mansour A, Charles S, Hostetler J, Settje T, Kulke D, et al. Efficacy evaluation of anthelmintic products against an infection with the canine hookworm (Ancylostoma caninum) isolate Worthy 4.1F3P in dogs. Int J Parasitol Drugs Drug Resist. 2020;13:22\u20137.","journal-title":"Int J Parasitol Drugs Drug Resist"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-026-07529-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-026-07529-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-026-07529-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:10:40Z","timestamp":1785521440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13071-026-07529-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7529"],"URL":"https:\/\/doi.org\/10.1186\/s13071-026-07529-4","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These studies were conducted in compliance with local and national regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NR, EZ and LH are employees of MSD Animal Health Innovation GmbH. RC is an employee of MSD Sa\u00fade Animal, and worked at MSD Animal Health Innovation GmbH at the time of study conduct. MSD Animal Health Innovation GmbH commissioned studies 2 and 4 to the University of Veterinary Medicine Hannover, where CS, MKR and AS work, and studies 1 and 3 to Iorras Product Development Ltd, a contract research organization, managed by AM. MS works at the University of Z\u00fcrich, where the serological analysis was conducted on behalf of MSD Animal Health Innovation GmbH.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"303"}}